Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical Genitourinary Cancer Année : 2023

Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide

Gwenaelle Gravis

Résumé

PURPOSE: Using large French retrospective study cohort of chemotherapy-naïve metastatic castration-resistant prostate cancer patients (mCRPC; n = 10,308) comparing survival between patients who initiated abiraterone (ABI; 64%) and those initiating enzalutamide (ENZ; 36%), the present objective was to describe treatment patterns in the 2 years following initiation. METHOD: Using the national health data system (SNDS) from 2014 to 2018, we first explored the number of treatment lines, and secondly, patterns of patient management using state sequence analysis; cluster analyses were performed on the 0 to 12 month and 13 to 24 month periods. Age, Charlson score, and duration of androgen deprivation therapy (ADT) were obtained for each cluster in the first year of follow-up. RESULTS: Patients with only 1 treatment line accounted for 52%. In the 0 to 12 month sequence analysis, the main clusters among ABI/ENZ new users involved patients who continued the initial treatment (54% of 65% respectively) and discontinued active treatment (14.5% for both). Less than 2 years exposure to ADT prior to ABI/ENZ initiation was frequently observed for noncontrolled mCRPC, as shown in the death and switch from ABI/ENZ to docetaxel clusters. The clusters for a switch ABI/ENZ to ENZ/ABI involved 6% to 11% of the patients. CONCLUSION: Our study suggested fairly similar patterns between ABI and ENZ initiation. The cluster of patients with active treatment discontinuation needs to be further investigated, as well as factors influencing therapeutic choice. Better understanding for the use of second-generation hormone therapy in mCRPC in real life, could improve its implementation by clinicians in the early stages of prostate cancer.
Fichier principal
Vignette du fichier
Scailteux et al - 2023 - Real-world treatment patterns among French patients.pdf (703.83 Ko) Télécharger le fichier
Scailteux_Appendix_revised_SPEAR_séquence.pdf (490.47 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04121016 , version 1 (12-06-2023)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Lucie-Marie Scailteux, Sebastien Vincendeau, Gwenaelle Gravis, Romain Mathieu, Frederic Balusson, et al.. Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide. Clinical Genitourinary Cancer, 2023, ⟨10.1016/j.clgc.2023.04.004⟩. ⟨hal-04121016⟩
63 Consultations
49 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More